StreetInsider.com News Articles

Lifecore Biomedical (LFCR) Tops Q2 EPS by 4c

Wed, 05 Aug 2026 07:32:43 -0400

Lifecore Biomedical (NASDAQ: LFCR) reported Q2 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $34.17 million versus the consensus estimate of $31.66 million.

For earnings history and earnings-related data on Lifecore Biomedical (LFCR) click here.

Form 10-Q LIFECORE BIOMEDICAL, For: Jun 30

Wed, 05 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260805/26870263.html

Form 10-Q LIFECORE BIOMEDICAL, For: Jun 30

Wed, 05 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260805/26870263.html

Form 10-Q LIFECORE BIOMEDICAL, For: Jun 30

Wed, 05 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260805/26870263.html

Form 8-K LIFECORE BIOMEDICAL, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870249.html

Form 8-K LIFECORE BIOMEDICAL, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870249.html

Form 8-K LIFECORE BIOMEDICAL, For: Aug 05

Wed, 05 Aug 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26870249.html

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CHASKA, Minn., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the second quarter and six months ended June 30, 2026.

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business

Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update

Wed, 05 Aug 2026 07:05:00 -0400

-- Reaffirms 2026 Guidance --

-- Multiple New Business Wins, Adding Impactful Programs to Pipeline --

-- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization --

Conference Call Today at 8:00am ET

CEO Commentary

“The second quarter was highly productive. The effectiveness of our new business

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Wed, 29 Jul 2026 16:05:00 -0400

CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens. At 8:00 a.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss the results.

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Wed, 29 Jul 2026 16:05:00 -0400

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Wed, 29 Jul 2026 16:05:00 -0400

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.

Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026

Wed, 29 Jul 2026 16:05:00 -0400

To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations.

Form SCHEDULE 13G LIFECORE BIOMEDICAL, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26834418.html

Form SCHEDULE 13G LIFECORE BIOMEDICAL, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26834418.html

Form SCHEDULE 13G LIFECORE BIOMEDICAL, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26834418.html

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 3,500 shares of its common stock under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 15 Jul 2026 16:05:00 -0400

The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: Legion Partners Asset Management, LLC

Thu, 02 Jul 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260702/26729706.html

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: Legion Partners Asset Management, LLC

Thu, 02 Jul 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260702/26729706.html

Form SCHEDULE 13D/A LIFECORE BIOMEDICAL, Filed by: Legion Partners Asset Management, LLC

Thu, 02 Jul 2026 17:37:00 -0400

si-local-file:///var/storage/secattach/20260702/26729706.html